Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Frequency doubling technology staging system 2.

Paolo Brusini1

  • 1Department of Ophthalmology, Santa Maria della Misericordia Hospital, Udine, Italy. brusini@libero.it

Journal of Glaucoma
|July 26, 2006
PubMed
Summary

A new staging system, FDT SS2, accurately classifies visual field defects from the Humphrey Matrix 30-2 test. This tool reliably stages severity and distinguishes defect types in glaucoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Artificial Intelligence Enabled System for Retinal Nerve Fiber Layer Thickness Damage Severity Staging.

Ophthalmology science·2023
Same author

Detecting glaucoma from multi-modal data using probabilistic deep learning.

Frontiers in medicine·2022
Same author

Use of an automatic refractometer as a screening tool for pigment dispersion syndrome detection.

Survey of ophthalmology·2022
Same author

It Is All about Pressure.

Journal of clinical medicine·2022
Same author

Editorial: Glaucoma and Brain: Impact of Neurodegeneration on Visual Abilities and Related Biomarkers.

Frontiers in aging neuroscience·2022
Same author

Canaloplasty in Pseudoexfoliation Glaucoma. Can It Still Be Considered a Good Choice?

Journal of clinical medicine·2022

Area of Science:

  • Ophthalmology
  • Visual Neuroscience
  • Medical Diagnostics

Background:

  • Visual field defects are common in glaucoma and ocular hypertension.
  • Accurate staging of these defects is crucial for patient management.
  • The Humphrey Matrix 30-2 threshold test is a widely used tool for visual field assessment.

Purpose of the Study:

  • To develop and validate a novel staging system, FDT SS2, specifically for visual field defects detected by the Humphrey Matrix 30-2 test.
  • To assess the system's ability to classify defect severity and type.

Main Methods:

  • The FDT SS2 was developed using data from normal subjects, ocular hypertension (OHT), and primary open-angle glaucoma (POAG) patients.
  • Its performance was evaluated on POAG patients using the Humphrey Matrix 30-2 test, with a modified Aulhorn and Karmeyer classification as the gold standard.
  • Reliability in categorizing defect types (generalized, mixed, localized) was compared to clinical analysis of probability maps.

Main Results:

  • FDT SS2 achieved 70.4% agreement in severity classification with the gold standard in POAG patients.
  • All classifications were within one level of the clinical grade.
  • The system demonstrated good reliability in distinguishing defect types (Spearman test: 0.719, P<0.001) and high specificity (93.7%) in normal subjects.

Conclusions:

  • The FDT SS2 is a reliable tool for staging visual field defect severity in patients tested with the Humphrey Matrix 30-2 threshold test.
  • It effectively differentiates between generalized, localized, and mixed defect types.
  • This system aids in the precise classification of functional damage in glaucoma.

Related Experiment Videos